Ann Oncol 2015; 26: 1459–1464 (doi: 10.1093/annonc/mdv171)
In the original article, the abstract listed the incorrect NCT number. It should have been NCT00720174. This has now been corrected.
. 2019 Dec 4;30(8):1405. doi: 10.1093/annonc/mdy557
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
R Chugh
, KA Griffith
, EJ Davis
, DG Thomas
, JD Zavala
, G Metko
, B Brockstein
, SD Undevia
, WM Stadler
, SM Schuetze
R Chugh
Find articles by R Chugh
KA Griffith
Find articles by KA Griffith
EJ Davis
Find articles by EJ Davis
DG Thomas
Find articles by DG Thomas
JD Zavala
Find articles by JD Zavala
G Metko
Find articles by G Metko
B Brockstein
Find articles by B Brockstein
SD Undevia
Find articles by SD Undevia
WM Stadler
Find articles by WM Stadler
SM Schuetze
Find articles by SM Schuetze
Issue date 2019 Aug.
© 2019 THE AUTHORS
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PMCID: PMC7360153 PMID: 30726873
This corrects the article "Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model" in volume 26 on page 1459.